VIDEO: Palbociclib may delay chemotherapy for some women with metastatic breast cancer

CHICAGO – PALOMA-3 lead study author, Dr. Nicholas C. Turner, discusses the phase III trial findings, which indicate the possibility of delaying chemotherapy in some women with metastatic breast cancer.

Dr. Turner, a consultant medical oncologist at The Royal Marsden and a team leader at The Institute of Cancer Research, London, says in an interview that the findings suggest the use of palbociclib—a first-in-class oral inhibitor of CDKs 4 and 6 that prevents cell cycle progression—may delay the need for chemotherapy in women with hormone receptor–positive, HER2-negative metastatic breast cancer that is showing resistance to endocrine therapy.

CHICAGO – PALOMA-3 lead study author, Dr. Nicholas C. Turner, discusses the phase III trial findings, which indicate the possibility of delaying chemotherapy in some women with metastatic breast cancer.

Dr. Turner, a consultant medical oncologist at The Royal Marsden and a team leader at The Institute of Cancer Research, London, says in an interview that the findings suggest the use of palbociclib—a first-in-class oral inhibitor of CDKs 4 and 6 that prevents cell cycle progression—may delay the need for chemotherapy in women with hormone receptor–positive, HER2-negative metastatic breast cancer that is showing resistance to endocrine therapy.

CHICAGO – PALOMA-3 lead study author, Dr. Nicholas C. Turner, discusses the phase III trial findings, which indicate the possibility of delaying chemotherapy in some women with metastatic breast cancer.

Dr. Turner, a consultant medical oncologist at The Royal Marsden and a team leader at The Institute of Cancer Research, London, says in an interview that the findings suggest the use of palbociclib—a first-in-class oral inhibitor of CDKs 4 and 6 that prevents cell cycle progression—may delay the need for chemotherapy in women with hormone receptor–positive, HER2-negative metastatic breast cancer that is showing resistance to endocrine therapy.